|
|
|
|
Vol. 60, Issue 3, 568-576, September 2001
3
4 Nicotinic Acetylcholine
Receptors Stably Expressed in Human Embryonic Kidney 293 Cells
Department of Pharmacology, Georgetown University School of Medicine, Washington, DC
| |
Abstract |
|---|
|
|
|---|
Effects of agonists on rat
3
4 nicotinic acetylcholine receptors
expressed in KX
3
4R2 cells [human embryonic kidney
293-derived cells] were studied. The potencies of seven agonists
varied over a 7000-fold range, with a rank order of epibatidine
A85380 > cytisine
1,1-dimethyl-4-phenyl-piperazinium
iodide (DMPP)
nicotine > acetylcholine > carbachol. The efficacies of all of the agonists studied here were
similar except for DMPP, which seemed to be a partial agonist compared
with nicotine and acetylcholine. Nicotine and carbachol desensitized
the receptors in a time- and concentration-dependent manner. The
EC50 values for nicotine and carbachol to desensitize the
receptors during a 60-min exposure were 3 and 51 µM, respectively,
indicating that these agonists are more potent at desensitizing the
receptors than at activating them. The function of the receptors
recovered from agonist-induced desensitization rapidly and almost
completely. The half-time for recovery of function from desensitization
after a 60-min treatment with nicotine increased with the concentration
of nicotine used to desensitize the receptors. In contrast, no such
concentration dependence for time to recovery of function was found
when carbachol was used to desensitize the receptors. We propose that
this difference may be due to the cell permeability of nicotine,
allowing it to enter and be sequestered inside of cells and then slowly
diffuse out to maintain receptor desensitization. After a 5-day
exposure to 100 µM nicotine, the receptors were completely
desensitized, but receptor function recovered to 83% of control values
with a half-time of about 10.5 min. Although the number of nicotinic receptor binding sites measured with
(±)-[3H]epibatidine was increased during the
chronic treatment with nicotine, no increase in function was detected.
| |
Introduction |
|---|
|
|
|---|
Neuronal
nicotinic receptors are expressed throughout the CNS and peripheral
nervous system. These receptors are composed of
and
subunits
and exist as subtypes defined by their particular subunit composition.
Nine different
subunits (
2-
10) and three different
subunits (
2-
4) have been identified in vertebrates to date,
indicating significant structural diversity among these receptor
subtypes. The range of functional properties and pharmacological characteristics among these receptors is primarily a direct reflection of this structural diversity.
One putative nicotinic receptor is the
3
4 subtype, composed of
3 and
4 subunits. This subtype or a close variant of it may be
one of the major nicotinic receptors in some autonomic ganglia (Conroy
and Berg, 1995
; Wong et al., 1995
; Poth et al., 1997
), sensory ganglia
(Flores et al., 1996
), and adrenal gland (Campos-Caro et al., 1997
), as
well as in several important regions of the CNS (Mulle et al., 1991
;
Winzer-Serhan and Leslie, 1997
; Zoli et al., 1998
; Quick et al., 1999
).
Recently, we established a transfected HEK 293 clonal cell line,
KX
3
4R2, that stably expresses a high density of functional
3
4 receptors (Xiao et al., 1998
; Zhang et al., 1999
). We have used these cells to characterize the pharmacology of the agonist binding site and the function of the
3
4 nicotinic receptor (Xiao et al., 1998
). We found, for example, that although all the nicotinic agonists examined have relatively high affinity for the
3
4
receptor binding sites, their affinities were much lower than in rat
forebrain, in which
4
2 receptors predominate (Whiting and
Lindstrom, 1987
; Flores et al., 1992
). In fact, the equilibrium
dissociation constants for acetylcholine, nicotine, and cytisine at
3
4 receptors are 200 to 800 nM (Xiao et al., 1998
). These
affinities are far too low to allow radioactive versions of these
agonists to effectively label these receptors directly, which probably
explains why these ligands have, in general, not been very useful as
radioligands for measuring the nicotinic receptors in ganglia and
adrenal gland, in which
3
4 receptors may predominate. In
contrast, epibatidine binds to these heterologously expressed
3
4
receptors with a dissociation constant of about 300 pM and is an
excellent radioligand for measuring them, as well as the receptors in
adrenal gland, autonomic, and central ganglia (Houghtling et al., 1995
;
Flores et al., 1996
; Dávila-García et al., 1997
).
In addition to information about the receptor binding site, studies in
these transfected cells showed that receptor function could be assessed
by measurements of [86Rb]rubidium chloride
(86Rb+) ion efflux,
Ca2+ ion imaging, Na+ ion
imaging, and with whole-cell patch-clamp methods (Xiao et al., 1998
;
Zhang et al., 1999
; Hernandez et al., 2000
). These studies indicated
that acetylcholine and nicotine are equally efficacious at activating
3
4 receptors; that mecamylamine, hexamethonium, and
d-tubocurarine are effective noncompetitive blockers; and that dihydro-
-erythroidine is a competitive blocker of
3
4
receptors (Xiao et al., 1998
).
Among the important properties of nicotinic receptors are their
propensity to desensitize during exposure to agonists and their rate of
recovery from desensitization. These properties vary among the
different receptor subtypes and may be critical in determining which
nicotinic receptors are able to respond to stimulation by endogenous
acetylcholine or exogenous agonists and to what degree they can
respond. Both
and
subunits seem to contribute to the
characteristics of desensitization of nicotinic receptors expressed
heterologously in oocytes (Cachelin and Jaggi, 1991
; Gross et al.,
1991
). We have used the KX
3
4R2 cells to further study agonist
effects at
3
4 receptors and to characterize their desensitization
and recovery from desensitization after short- and long-term exposure
to nicotinic agonists.
| |
Experimental Procedures |
|---|
|
|
|---|
Materials and Drugs. Tissue culture medium, fetal bovine serum and antibiotics were obtained from Invitrogen (Carlsbad, CA). (±)-[3H]epibatidine ([3H]EB) and 86Rb+ were supplied by PerkinElmer Life Science Products (Boston, MA). All other chemicals were purchased from Sigma Chemical (St. Louis, MO) unless otherwise stated.
Cell Culture.
The cell line KX
3
4R2 was established
previously by stably cotransfecting HEK 293 cells with the rat
3 and
4 nAChR subunit genes (Xiao et al., 1998
). KX
3
4R2 cells were
grown as described previously (Xiao et al., 1998
) in minimum essential
medium supplemented with 10% fetal bovine serum, 100 units/ml
penicillin G, 100 µg/ml streptomycin, and 0.7 mg/ml Geneticin (G418)
at 37°C with 5% CO2 in a humidified incubator.
86Rb+ Efflux Assay.
Functional
properties of the nAChRs expressed in the KX
3
4R2 cells were
assessed by measurements of nicotinic agonist-stimulated 86Rb+ efflux, as described
previously (Xiao et al., 1998
). In brief, aliquots of cells in the
selection growth medium were plated into 24-well plates coated with
poly-D-lysine. The plated cells were grown at 37°C for 18 to 24 h to reach 70 to 95% confluence. The cells were then
incubated in growth medium (0.5 ml/well) containing 86RbCl (2 µCi/ml) for 4 h at 37°C, the
loading mixture was aspirated, and the cells were washed four times
with HEPES buffer (15 mM HEPES, 140 mM NaCl, 2 mM KCl, 1 mM
MgSO4, 1.8 mM CaCl2, 11 mM glucose, pH 7.4; 1 ml/well). One milliliter of buffer, with or without
agonists, was then added to each well. After incubation for 2 min, the
assay buffer was collected and the amount of
86Rb+ in the buffer was
determined. Cells were then lysed by adding 1 ml of 100 mM NaOH to each
well, and the lysate was collected for determination of the amount of
86Rb+ in the cells at the
end of the efflux assay. Radioactivity of assay buffer samples and
lysates was measured by liquid scintillation counting. Total amount of
86Rb+ loaded (counts per
minute) was calculated as the sum of the assay buffer sample and the
lysate of each well. The amount of
86Rb+ efflux was expressed
as a percentage of 86Rb+
loaded. Stimulated 86Rb+
efflux was defined as the difference between efflux in presence of
nicotinic agonists and basal efflux measured in the absence of
agonists. Basal 86Rb+
efflux ranged from 3 to 6% and maximal stimulated efflux was approximately 45% of loaded
86Rb+. Nonlinear regression
analyses and statistical analyses were performed using Prism software
(GraphPad Software, San Diego, CA).
Radioligand Binding Assay.
To measure effects of long-term
treatment with nicotine on
3
4 receptor density, cells were
cultured in the presence or absence of nicotine for the times
indicated. Binding of [3H]EB to receptors was
then measured as described previously (Xiao et al., 1998
), with minor
modifications. Briefly, the cells were harvested in 50 mM Tris·HCl,
pH 7.4, washed, homogenized with the use of Brinkmann polytron
homogenizer (Brinkmann Instruments, Westbury, NY), and
centrifuged at 35,000g. The pellets were washed three times
by suspension in fresh buffer and centrifugation at 35,000g.
The resulting washed membranes were then incubated with approximately 3 nM [3H]EB for 4 h at 24°C in a final
volume of 1 ml. Nonspecific binding was assessed in parallel
incubations in the presence of 300 µM nicotine. Bound and free
ligands were separated by vacuum filtration through Whatman GF/C
filters (Whatman, Clifton, NJ) treated with 0.5%
polyethylenimine. The filter-retained radioactivity was measured by
liquid scintillation counting. Specific binding was defined as the
difference between total binding and nonspecific binding.
| |
Results |
|---|
|
|
|---|
Agonist Stimulation of
3
4 Nicotinic Receptors.
Concentration response curves for seven nicotinic agonists stimulating
86Rb+ efflux via
3
4
receptors in KX
3
4R2 cells are shown in Fig. 1 and the potency
(EC50) and relative efficacy
(Emax) for each drug is shown in Table
1. The potencies of the agonists varied over a 7,000-fold range, from 60 nM for EB to 440 µM for carbachol (Table 1). The rank order of potency for stimulating
86Rb+ efflux in these
studies was EB
A85380 > cytisine
DMPP
nicotine > acetylcholine > carbachol (Table 1). Nicotine
was approximately 4 times more potent than acetylcholine but 500 times less potent than EB. Interestingly, A85380, which has very high
affinity for
4
2 nicotinic receptor binding sites (Sullivan et
al., 1996
; Xiao et al., 1998
; Mukhin et al., 2000
) but about 750 times
lower affinity for
3
4 receptor binding sites (Xiao et al., 1998
;
Mukhin et al., 2000
), was nevertheless the second most potent agonist
at activating
3
4 receptors; in fact, A85380 was about 5 times
more potent than nicotine, although it was still about 90 times less
potent than EB.
|
|
Time Course- and Concentration-Dependence of
3
4 Receptor
Desensitization by Agonists.
Nicotinic receptors desensitize
during exposure to agonists. This loss of responsiveness is usually
both time- and concentration-dependent (Marks et al., 1994
), but these
parameters vary according to the receptor subtype (Fenster et al.,
1997
). To examine the time course of desensitization of the
3
4
receptors, we treated the cells with nicotine for different time
periods and then, after removing the nicotine-containing media,
immediately measured the receptor-mediated 86Rb+ efflux response
elicited by 100 µM nicotine, a nearly maximally effective
concentration. When the receptor response was measured immediately
after exposure to 10 or 100 µM nicotine for different time periods,
the response decreased in an exponential manner with half-times of
about 11 min after exposure to 10 µM nicotine and 1 min after
exposure to 100 µM nicotine (Fig. 2).
The response to nicotine was decreased by approximately 90% after
exposure to 10 µM nicotine for 60 min, and by at least 94% after
exposure to 100 µM nicotine for 60 min (Fig. 2). In contrast, after
exposure to 1 µM nicotine for 60 min, the response was decreased by
only about 27% (Fig. 2), and nonlinear regression analysis projected it to reach plateau at approximately 58% of control with a half-time of 41 min.
|
3
4 receptors
by nicotine and by carbachol was examined by treating cells with a wide
range of concentrations of these agonists for 60 min and then,
immediately after removing the agonists, measuring the 86Rb+ efflux response
elicited by 100 µM nicotine. As shown in Fig. 3, the EC50 values
for nicotine and carbachol to desensitize these
3
4 receptors
during the 60-min exposure were about 3 and 51 µM, respectively, and
receptor function was completely eliminated by treatment with 100 µM
nicotine or 1000 µM carbachol. For both drugs, the slope of the Hill
function was close to 1 (Fig. 3).
|
Recovery from Desensitization.
We next examined the rate at
which these
3
4 nicotinic receptors recover from desensitization
and whether that rate is dependent upon the concentration of the
agonist that induced the desensitization. The receptors were
desensitized by incubation of the cells with either 100 or 300 µM
nicotine or 1000 or 3000 µM carbachol for 60 min. The agonists were
then removed and 86Rb+
efflux stimulated by 100 µM nicotine was measured either immediately or after the cells were washed and allowed to recover in buffer for
increasing amounts of time.
3
4 nicotinic
receptors began to return almost immediately, and within 40 min in
recovery buffer reached about 75% of the response measured in control
cells that had been preincubated for 60 min in the absence of nicotine.
The recovery of receptor response after the 60-min exposure to 100 and
300 µM nicotine seemed to reach a plateau at approximately 93% and
83% of control responses, respectively (Table
2 and Fig. 4). However, the rate of
return of receptor sensitivity was related to the concentration of
nicotine used to induce desensitization (Fig. 4). Thus, as shown in
Table 2, the half-times for the recovery of the nicotinic
receptor-mediated response after cells were treated with 100 or 300 µM nicotine were 7 or 12 min, respectively (P < 0.01).
|
|
Effects of Chronic Treatments with Nicotine on
3
4 Receptor
Function.
Prolonged exposure of some nicotinic receptors to high
concentrations of nicotinic agonists is sometimes associated with loss of function that persists well beyond the presumed removal of the
agonist. This phenomenon, referred to as receptor inactivation (Aoshima, 1984
), has been seen in a wide variety of cell types. To
determine whether these
3
4 receptors are subject to inactivation, we grew cells in medium containing nicotine for up to 5 days before measuring receptor function. As expected based on the results from the
60-min exposure to nicotine shown in Fig. 3, when cells were exposed to
100 µM nicotine for 1, 3, or 5 days and assayed immediately after
removal of the nicotine-containing medium, nicotine-stimulated 86Rb+ efflux was
essentially abolished (Fig. 5). Studies
of the concentration-dependence of this loss of receptor function
during a 5-day exposure to nicotine yielded an
EC50 value of 1.3 ± 0.1 µM (Fig.
6), which, although statistically
different (p < 0.01) from that seen after incubation with nicotine for 60 min (3.2 ± 0.3 µM; see legend to Fig. 3), is surprisingly similar considering the different times of exposure. An
important test for inactivation of receptors is whether or not the loss
of receptor function is irreversible over a period of time that would
exclude synthesis of new receptors as an explanation for return of
function. To examine this, we grew cells for 5 days in the presence of
100 µM nicotine and then measured nicotine-stimulated function after
washing the cells and allowing them to recover in nicotine-free medium
for increasing periods of time, up to 1 day. Immediately after this
5-day exposure to nicotine, no receptor function was measurable.
However, as shown in Fig. 7, even after this prolonged exposure to nicotine, receptor function began to return
within a few minutes in recovery buffer and reached approximately 80%
of the responses in control cells within 2 h. The half-time for
return of function was 11 ± 0.6 min, which, although
statistically different (P < 0.01) from that seen
after treatment of cells with the same concentration of nicotine for
only 60 min (7.0 ± 0.5 min), is surprisingly similar. Recovery of
receptor function after 5 days' exposure to nicotine was incomplete
(Fig. 7), and even after 24 h of recovery in nicotine-free medium,
function remained at 83 ± 1.2% of that in control cells. The
difference in the degree of recovery of function after treatment with
100 µM nicotine for 60 min (93 ± 2%, Table 2) versus 5 days
was statistically significant (P < 0.01).
|
|
|
Effects of Chronic Treatments with Nicotine on [3H]EB
Binding Sites.
The density of some, but not all, nicotinic
receptor subtypes is increased after chronic exposure of rats or mice
to nicotine in vivo (Marks et al., 1983
; Schwartz and Kellar, 1983
;
Flores et al., 1992
, 1997
). Similarly, the density of some nicotinic receptor subtypes expressed in cultured cells is increased by exposure
to nicotine for several days, but the degree of increase is
subtype-dependent (Peng et al., 1997
; Wang et al., 1998
; Xiao et al.,
2000b
). In particular, the
subunit seems to be an important determinant of whether or how much the receptor increases during exposure to nicotine (Wang et al., 1998
). To determine whether
3
4
receptors in these cells are increased by exposure to nicotine, [3H]EB binding was measured in cells grown for
5 days in the presence of nicotine at concentrations of 1 to 1000 µM.
Binding was measured at a single high concentration of
[3H]EB (3 nM), which provides a good estimate
of the density of receptor binding sites. As shown in Fig.
8A, continuous exposure of cells to
concentrations of nicotine as low as 1 µM for 5 days significantly
increased the density of
3
4 receptor binding sites labeled by
[3H]EB. The increase was
concentration-dependent and ranged from about 200% of control to more
than 350% of control. Examination of the time course of changes in
[3H]EB binding during incubation with 100 µM
nicotine indicated that within 24 h of exposure to nicotine, the
number of receptor binding sites was significantly increased to 174%
of control and that the receptors continued to increase during the next
4 days of continuous exposure to nicotine, so that after 5 days of
exposure to nicotine, the density of receptors had tripled (Fig. 8B).
|
| |
Discussion |
|---|
|
|
|---|
The KX
3
4R2 cells express a high density of
3
4
nicotinic receptors and provide a good model system for the study of
receptor function (Xiao et al., 1998
; Zhang et al., 1999
). Here we
examined the pharmacological profile of
3
4 receptor activation by
nicotinic agonists and studied some of the characteristics of receptor
desensitization and recovery of function after short-term (up to 60 min) and during long-term (1 to 5 days) exposures to agonists.
The seven nicotinic agonists studied here exhibited a >7000-fold range
of potencies in stimulating
86Rb+ efflux. EB is by far
the most potent of the drugs examined, being 95 times more potent than
the second ranked drug, A85380, 500 times more potent than nicotine,
and >1000 times more potent than acetylcholine. The rank order of
potency is consistent with that found previously in measurements of
whole-cell currents mediated by rat recombinant
3
4 receptors
transiently expressed in HEK 293 cells (Wong et al., 1995
), and it is
very similar to that found in measurements of whole-cell currents
mediated by human
3
4 receptors expressed in Xenopus
laevis oocytes (Gerzanich et al., 1997
), as well as in
measurements of calcium influx mediated by the human
3
4 receptor
expressed in HEK 293 cells (Stauderman et al., 1998
).
Compared with nicotine, all of the agonists studied here appeared to be
full or nearly full agonists at the
3
4 receptor, except for DMPP,
which produced about 67% of the response elicited by nicotine. This
result agrees with a previous study that measured whole-cell currents
in cells transiently expressing rat
3
4 receptors (Wong et al.,
1995
). However, in studies with human recombinant
3
4 receptors,
DMPP seemed to be as efficacious as nicotine in stimulating calcium
influx (Stauderman et al., 1998
). Whether this represents a true
species difference or a difference attributable to the methods used to
assess function is not known. The full agonist activity of cytisine at
these
3
4 receptors agrees with previous measurements in frog
oocytes expressing rat
3
4 receptors (Luetje and Patrick, 1991
;
Papke and Heinemann, 1994
), as well as in mammalian cells transfected
with rat (Wong et al., 1995
) and human (Stauderman et al., 1998
)
3
4 receptors. Taken together, the pharmacological profile of
these recombinant receptors should help to provide a framework useful
for identifying
3
4 receptors in native tissues.
Both nicotine and carbachol desensitize these receptors in a time- and
concentration-dependent manner. As would be expected, the half-times
for desensitization were inversely related to the concentration of
nicotine; thus, at 1 µM nicotine, the time for half-maximal
desensitization was estimated to be about 41 min; at 10 µM nicotine,
it was 11 min; and at 100 µM nicotine, it was just over 1 min. The
EC50 values for nicotine and carbachol to desensitize
3
4 receptors were 3 and 51 µM, respectively, when the incubation time was 60 min. These concentrations are approximately 10 and 9 times lower, respectively, than the EC50
values for activation of the receptor by these agonists. In fact, at
the EC50 concentrations for desensitization, the
3
4 receptor would barely be activated (<10%, see Fig. 1). Thus,
nicotinic agonists are more potent at desensitizing these receptors
than at activating them. A similar conclusion has been drawn from
previous studies of nicotinic receptors in other systems in vitro
(Boyd, 1987
; Marks et al., 1994
; Rowell and Hillebrand, 1994
) and in
vivo (Hulihan-Giblin et al., 1990a
). However, activation occurs in the
millisecond to second time frame, whereas desensitization probably
takes place over a longer time frame.
The
3
4 receptor function began to recover from nicotine-induced
desensitization nearly immediately after the cells were washed and
placed in recovery buffer. After a 60-min treatment of cells with 300 and 100 µM nicotine, function recovered to 83 and 93% of control
values, respectively. Although in both cases recovery seemed to be
nearly complete at about 80 min after placing the cells in
nicotine-free medium, the rate of recovery was related to the
concentration of nicotine used to induce desensitization. The influence
of concentration of agonist on the rate of recovery from
desensitization is not immediately predictable from the classic model
of desensitization derived from studies of the muscle nicotinic receptor (Katz and Thesleff, 1957
), although it is not necessarily irreconcilable with that model. It could, for example, indicate that
induction of and recovery from desensitization involve more than one
process (Marks et al., 1994
; Rowell and Duggan, 1998
). To investigate
this further, we examined the rate of recovery from carbachol-induced
desensitization. Immediately after a 60-min treatment of cells with
1000 or 3000 µM carbachol, receptor function was decreased by >95%,
indicating that the receptors were desensitized. As was seen after the
60-min treatment with nicotine, when the cells were washed and placed
in recovery buffer, receptor function began to return almost
immediately. However, the recovery from carbachol-induced
desensitization was not only faster and more complete than that from
nicotine but also was independent of the concentration of carbachol
used to induce desensitization. This suggests that recovery from
carbachol-induced desensitization involves a simple process, rather
than a more complex mechanism.
One plausible explanation for the differences in recovery from similar
degrees of desensitization induced by nicotine and carbachol is that
recovery is related to the agonist's dissociation rate from the
receptor. On this basis alone, nicotine, because of its higher
affinity, would be expected to have a slower rate of dissociation from
the receptor, and receptor recovery would therefore be slower. In
addition, nicotine is lipophilic and easily crosses cell membranes, so
it may be sequestered inside cells. When the cells are washed and
placed in nicotine-free medium, the nicotine inside the cells would be
expected to diffuse down its concentration gradient to the
extracellular medium, where it could then bind to cell-surface
receptors and maintain a certain degree of desensitization. This would,
of course, be concentration dependent, and when the extracellular
concentration of nicotine dropped below the threshold for receptor
desensitization, recovery would be complete. This hypothesis is
consistent with a recent observation by Cohen and colleagues who found
that nicotine can accumulate in and diffuse from X. laevis
oocytes at concentrations high enough to desensitize
4
2 receptors
expressed in oocytes not previously exposed to nicotine (B. Cohen,
University of California, Riverside, personal communication). This
hypothesis is also consistent with a recent finding indicating that
changes in sensitivity of nicotinic receptors expressed in X. laevis oocytes upon long-term exposure to nicotine result from
effects at the extracellular domain of the
subunit (Kuryatov et
al., 2000
). Carbachol, on the other hand, is a lower affinity, charged
quaternary ammonium agonist that does not readily cross cell membranes.
Consequently, it is not sequestered inside cells and should be removed
rapidly and completely by the washing procedure. According to this
explanation,
3
4 receptor desensitization and recovery of function
after exposure to nicotinic agonists for up to 60 min are probably
governed by simple processes directly related to agonist occupancy of
and removal from the receptor.
There are other possible explanations for the observed differences in
recovery of receptor function after exposure to nicotine and carbachol.
But if, in fact, nicotine in the brain could be sequestered in and
diffuse out of neurons and glial cells, it would have important
consequences for its pharmacological actions and the interpretation of
its effects. Thus, for example, it could allow nicotine to maintain
neuronal nicotinic receptors in a fully or partially desensitized state
for prolonged periods by simple diffusion out of the cell. Moreover,
because nicotine's affinity for the
4
2 receptor subtype, which
is one of the major nicotinic receptors in brain, is 5- to 8-fold
higher than for the
3
4 subtype, desensitization would be expected
at nicotine concentrations lower than those seen here.
In addition to desensitization, which occurs and reverses over a
time-frame of seconds to minutes, the function of some nicotinic receptors may be inactivated by a much less reversible process, which
usually becomes apparent only during longer-term exposure to nicotinic
agonists. Inactivation of nicotinic receptors to varying degrees has
been found in studies in a variety of tissues, including electric
tissue (Aoshima, 1984
), neuronal cell lines (Simasko et al., 1986
;
Boyd, 1987
; Lukas, 1991
), X. laevis oocytes (Kuryatov et
al., 2000
), and in brain slices and synaptosomes (Marks et al., 1994
;
Rowell and Duggan, 1998
). One in vivo manifestation of receptor
inactivation may be the long-term loss (hours to days) of
nicotine-induced hormonal responses in rats chronically treated with
nicotine (Sharp et al., 1987
; Hulihan-Giblin et al., 1990b
). The
3
4 receptors studied here recover more than 80% of their function within 2 h after removal from a 5-day continuous exposure to a high concentration of nicotine. Furthermore, the half-time for
return of receptor function after this 5-day exposure to nicotine is
similar to that after exposure to nicotine for only 60 min (11 min
versus 7 min). Based on this, these
3
4 receptors do not seem to
undergo extensive inactivation. To the extent that this resistance to
inactivation is also a characteristic of native
3
4 receptors, it
could have important consequences. For example, even in tissues and CNS
areas in which the
3
4 receptor is less dense than other nicotinic
receptor subtypes, it may exert a disproportionate influence on cell
function if the other subtypes undergo extensive inactivation.
There was, however, a 17% loss of receptor function that seemed to be irreversible within the 24-h recovery period that was examined. Whether this irreversible loss of receptor function reflects the process of inactivation, a shift in the equilibrium between the resting (activatable) conformation of the receptor and the desensitized conformation, or a cellular process such as receptor internalization is not known.
The number of
3
4 receptors in these cells was increased by
exposure to nicotine in a time- and concentration-dependent manner; thus, receptor binding sites doubled after a 5-day exposure to 1 µM
nicotine and were increased by more than 3-fold in cells exposed to
higher concentrations of nicotine. This increase in
3
4 receptor
binding sites contrasts with a recent report that found that human
3
4 nicotinic receptors expressed in cells derived from the HEK
293 cell line were not significantly increased by exposure to nicotine
for up to 48 h (Wang et al., 1998
). There are certain
methodological differences between the two studies, such as binding to
total cell membrane preparations versus binding to soluble nAChRs, but
we cannot exclude the possibility of a species difference between rat
and human receptor. However, we believe a likely explanation for the
difference is that the nicotine-induced increase of receptors in the
cells used here reflects a faster rate of receptor turnover.
The
subunit seems to be an important determinant of the degree of
up-regulation of the nicotinic receptor binding site. For example, in
transfected cells, receptors containing
2 subunits are, in general,
increased much more than those containing
4 subunits (Wang et al.,
1998
; Xiao et al., 2000b
). This may reflect a more pronounced effect of
nicotine on the assembly and/or turnover of
2-containing receptors
than on
4-containing receptors (Wang et al., 1998
). Although it is
difficult to make a precise comparison between receptors in transfected
cells and native receptors in mammalian nervous system, it is notable
that whereas
4
2 nicotinic receptors in rat brain are increased by
chronic administration of nicotine (Flores et al., 1992
), the nicotinic
receptors in adrenal gland, superior cervical ganglia, and pineal
gland, which seem to be predominantly
3
4 receptors, are not
increased (Flores et al., 1997
; Dávila-García and Kellar,
1998
). One explanation for the failure of chronic nicotine
administration to increase neuronal nicotinic receptors in these
peripheral tissues is that the increase may be directly related to the
turnover rate of the receptors. Thus, if the receptor turnover rate in
peripheral neurons was low compared with the rate in these cells, there
would be a proportionately smaller increase in the receptor density
over the time period of chronic administration.
The increased density of receptors found in the studies here did not
lead to a measurable increase in receptor function in the cells.
Previous studies demonstrated that [3H]EB binds
not in cells expressing either
3 or
4 subunits alone, only in
cells expressing both subunits (Xiao et al., 1998
). Furthermore, although expression of both subunits in a single binding entity is the
minimum requirement for endowing the cell with functional nicotinic
receptors, it does not assure function. Thus, although the
3
4 receptors normally expressed in these cells function at a high
level (Xiao et al., 1998
; Zhang et al., 1999
), it is possible that the
additional [3H]EB binding sites reflect a pool
of assembled receptors that are no longer, or possibly never were, on
the cell surface. Such a nicotine-induced increase in an intracellular
pool of receptors in cells expressing
4
2 receptors has been
reported (Whiteaker et al., 1998
). If the differences between the
functional and nonfunctional pools of nicotinic receptors are better
understood, it could open the possibility to increasing nicotinic
receptor function in conditions thought to involve these receptors,
including Alzheimer's disease, Tourette's syndrome, attention deficit
disorder, and nicotine addiction.
| |
Acknowledgments |
|---|
We thank Parul Mehta and Heather Davis for their assistance with tissue culture.
| |
Footnotes |
|---|
Received January 2, 2001; Accepted May 24, 2001
This work was supported by National Institutes of Health Grants
DA06486 and DA12976. E.L.M. was supported by National Institute of
Health Predoctoral Fellowship Grant DA05739. A preliminary report of
this work has been presented previously [Meyer EL, Xiao Y and Kellar
KJ (1997) Pharmacology of the function of the
3
4 neuronal
nicotinic receptor subtype stably expressed in transfected HEK cells.
Soc Neurosci Abstr 23:385]. Erin L. Meyer and Yingxian Xiao made equal contributions to this research and should be considered joint first authors of this report.
Kenneth J. Kellar, Department of Pharmacology, Georgetown University School of Medicine, Washington, DC 20007. E-mail: kellark{at}georgetown.edu
| |
Abbreviations |
|---|
CNS, central nervous system; 86Rb+, [86Rb]rubidium chloride; EB, (±)-epibatidine; HEK, human embryonic kidney; nAChR, nicotinic acetylcholine receptor; DMPP, 1,1-dimethyl-4-phenyl-piperazinium iodide.
| |
References |
|---|
|
|
|---|
subunits determine the time course of desensitization in rat
3 neuronal nicotinic acetylcholine receptors.
Pflueg Arch Eur J Physiol
419:
579-582[Medline].
3
4, a novel subtype in the mammalian nervous system.
J Neurosci
16:
7892-7901
4 and
2 subunits and is up-regulated by chronic nicotine treatment.
Mol Pharmacol
41:
31-37[Abstract].
6 nicotinic AChR subunit can form a functional heteromeric acetylcholine receptor.
Mol Pharmacol
51:
320-327
3
4 neuronal nicotinic receptors.
J Pharmacol Exp Ther
293:
962-967
- and
-subunits contribute to the agonist sensitivity of neuronal nicotinic acetylcholine receptors.
J Neurosci
11:
837-845[Abstract].
4
2 subtype-selective ligand for nicotinic acetylcholine receptors.
Mol Pharmacol
57:
642-649
2 subunit.
Mol Pharmacol
45:
142-149[Abstract].
3 and
7 acetylcholine receptor subtypes expressed by the human neuroblastoma cell line SH-SY5Y.
Mol Pharmacol
51:
776-784
3
4 subunit-containing nicotinic receptors dominate function in rat medial habenula neurons.
Neuropharmacology
38:
769-783[Medline].
2
4,
3
4 and
4
4 stably expressed in HEK 293 cells.
J Pharmacol Exp Ther
284:
777-789
4
2 nicotinic acetylcholine receptor ligand.
Neuropharmacology
35:
725-734[Medline].
3
2 but not
3
4 acetylcholine receptors stably transfected in human embryonic kidney cells.
J Biol Chem
273:
28721-28732
4
2 nicotinic acetylcholine receptors in M10 cells: pharmacological and spatial definition.
Mol Pharmacol
53:
950-962
3 and
4 mRNAs during rat brain development.
J Comp Neurol
386:
540-554[Medline].
3
4, expressed in transfected eucaryotic cells.
Mol Brain Res
28:
101-109[Medline].
3
4 neuronal nicotinic receptor function: maximum responses, potencies for activation and potencies for inhibition.
Soc Neurosci Abstr
26:
371.
3
4 subtype of neuronal nicotinic acetylcholine receptor stably expressed in a transfected cell line: pharmacology of ligand binding and function.
Mol Pharmacol
54:
322-333
3
4 neuronal nicotinic acetylcholine receptor.
Mol Pharmacol
55:
970-981
2 mutant mice.
J Neurosci
18:
4461-4472This article has been cited by other articles:
![]() |
M. Ohtani, T. Oka, M. Badyuk, Y. Xiao, K. J. Kellar, and J. W. Daly Mouse beta-TC6 Insulinoma Cells: High Expression of Functional {alpha}3beta4 Nicotinic Receptors Mediating Membrane Potential, Intracellular Calcium, and Insulin Release Mol. Pharmacol., March 1, 2006; 69(3): 899 - 907. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Beckel, A. Kanai, S.-J. Lee, W. C. de Groat, and L. A. Birder Expression of functional nicotinic acetylcholine receptors in rat urinary bladder epithelial cells Am J Physiol Renal Physiol, January 1, 2006; 290(1): F103 - F110. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Kuryatov, J. Luo, J. Cooper, and J. Lindstrom Nicotine Acts as a Pharmacological Chaperone to Up-Regulate Human {alpha}4{beta}2 Acetylcholine Receptors Mol. Pharmacol., December 1, 2005; 68(6): 1839 - 1851. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. B. Free, S. B. McKay, P. D. Gottlieb, R. T. Boyd, and D. B. McKay Expression of Native {alpha}3{beta}4* Neuronal Nicotinic Receptors: Binding and Functional Studies Investigating Turnover of Surface and Intracellular Receptor Populations Mol. Pharmacol., June 1, 2005; 67(6): 2040 - 2048. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Alkondon and E. X. Albuquerque Nicotinic Receptor Subtypes in Rat Hippocampal Slices Are Differentially Sensitive to Desensitization and Early in Vivo Functional Up-Regulation by Nicotine and to Block by Bupropion J. Pharmacol. Exp. Ther., May 1, 2005; 313(2): 740 - 750. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. K. Rau, R. D. Johnson, and B. Y. Cooper Nicotinic AChR in Subclassified Capsaicin-Sensitive and -Insensitive Nociceptors of the Rat DRG J Neurophysiol, March 1, 2005; 93(3): 1358 - 1371. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. C. Hernandez, S. Vicini, Y. Xiao, M. I. Davila-Garcia, R. P. Yasuda, B. B. Wolfe, and K. J. Kellar The Nicotinic Receptor in the Rat Pineal Gland Is an {alpha}3{beta}4 Subtype Mol. Pharmacol., October 1, 2004; 66(4): 978 - 987. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Xiao and K. J. Kellar The Comparative Pharmacology and Up-Regulation of Rat Neuronal Nicotinic Receptor Subtype Binding Sites Stably Expressed in Transfected Mammalian Cells J. Pharmacol. Exp. Ther., July 1, 2004; 310(1): 98 - 107. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. L. Parker, Y. Fu, K. McAllen, J. Luo, J. M. McIntosh, J. M. Lindstrom, and B. M. Sharp Up-Regulation of Brain Nicotinic Acetylcholine Receptors in the Rat during Long-Term Self-Administration of Nicotine: Disproportionate Increase of the {alpha}6 Subunit Mol. Pharmacol., March 1, 2004; 65(3): 611 - 622. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. N. Nguyen, B. A. Rasmussen, and D. C. Perry Subtype-Selective Up-Regulation by Chronic Nicotine of High-Affinity Nicotinic Receptors in Rat Brain Demonstrated by Receptor Autoradiography J. Pharmacol. Exp. Ther., December 1, 2003; 307(3): 1090 - 1097. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P. Boorman, M. Beato, P. J. Groot-Kormelink, S. D. Broadbent, and L. G. Sivilotti The Effects of {beta}3 Subunit Incorporation on the Pharmacology and Single Channel Properties of Oocyte-expressed Human {alpha}3{beta}4 Neuronal Nicotinic Receptors J. Biol. Chem., November 7, 2003; 278(45): 44033 - 44040. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Avila, M. I. Davila-Garcia, V. S. Ascarrunz, Y. Xiao, and K. J. Kellar Differential Regulation of Nicotinic Acetylcholine Receptors in PC12 Cells by Nicotine and Nerve Growth Factor Mol. Pharmacol., October 1, 2003; 64(4): 974 - 986. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. W. Fitch, Y. Xiao, K. J. Kellar, and J. W. Daly Membrane potential fluorescence: A rapid and highly sensitive assay for nicotinic receptor channel function PNAS, April 15, 2003; 100(8): 4909 - 4914. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Abdrakhmanova, J. Dorfman, Y. Xiao, and M. Morad Protons Enhance the Gating Kinetics of the alpha 3/beta 4 Neuronal Nicotinic Acetylcholine Receptor by Increasing Its Apparent Affinity to Agonists Mol. Pharmacol., February 1, 2002; 61(2): 369 - 378. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||